Therapeutic applications of flint polypeptides
CA 2358508 A1 · Owner: Eli Lilly And Company · Inventors: Posada, James Arthur; Cohen, Fredric Jay; Wierda, Daniel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Mature FLINT protein (mFLINT) binds FasL and LIGHT and prevents FasL-Fas , interaction. mFLINT inhibits FasL-Fas-mediated apoptotic and proinflammatory activity, and is useful in treating disorders that may be associated with abnormal apoptosis and inflammation. The invention provides the amino acid and nucleotide sequences of FLINT and mature FLINT. Therapeutic compositions and methods of treatment utilizing mFLINT also are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 21, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 21, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 21, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.